Personalised mRNA cancer vaccine

We had some exciting news for Moderna, a holding in our Global Fund and Merck today. Their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, in combination with Merck's anti-PD-1 therapy, KEYTRUDA, was granted Breakthrough Therapy Designation by the FDA for the adjuvant treatment of patients with high-risk melanoma following complete resection. The designation was based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. This is the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial, potentially representing a new frontier in treating melanoma and other cancers.

We are invested in Moderna because we are excited about the potential of mRNA vaccines to revolutionize the treatment of various diseases beyond COVID-19. We are looking forward to the company reaching more milestones in the future.

This note has been prepared by ELM Responsible Investments (‘ELMRI’) ABN 70 607 177 711 AFSL 520428, for Australian wholesale clients for the purposes of section 761G of the Corporations Act 2001 (Cth).

The information is not intended for general distribution or publication and must be retained in a confidential manner. Information contained herein consists of confidential proprietary information constituting the sole property of ELMRI and its investment activities; its use is restricted accordingly.

This note is for general informational purposes only and does not purport to be comprehensive or to give advice. The views expressed are the views of the writer at the time of preparation and presenting and all forecasts, assumptions, opinions, data and other information are not warranted as to accuracy or completeness and are subject to change without notice. This is not an offer document and does not constitute an offer or invitation of investment recommendation to distribute or purchase securities, shares, units or other interests to enter into an investment agreement. No person should rely on the content and/or act on the basis of any material contained in this note. Any potential investor should consider their own circumstances and seek professional advice.

ELMRI funds, its directors, employees, representatives and associates may have an interest in the named securities.

Past performance is for illustrative purposes only and is not indicative of future performance.